Phase 1 Trial A Phase 1 trial by Gamida Cell is examining a new potential treatment option for patients with multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma who have not responded…
According to a story from ASH Clinical News, the treatment of younger patients with multiple myeloma, a form of rare blood cancer, requires physicians to take into account certain factors…
The very first patient in Medigene AG's clinical trial examining MDG1011 has officially received the treatment. This is the company's first human clinical trial for this TCR therapy. The trial…
What is the Patient Advocate Foundation? The Patient Advocate Foundation (PAF) is a non-profit, formed in 1994 that has one primary aim- eliminate the barriers to treatment too many patients…
Multiple Myeloma Multiple Myeloma is a rare form of cancer that develops in the body's plasma cells. These cells are normally responsible for helping the body fight infection. The accumulation…
We've made a lot of progress in cancer research in recent years. Many novel therapies have been developed for illnesses previously considered untreatable. However, as new treatments have been discovered,…
The government shutdown hasn't had any startling affects on rare disease research yet, but drug developers have voiced their concern that it could soon begin to hinder the research process.…
"People always say that 'cancer doesn't discriminate,' but the healthcare system often does," -Liz Margolies, LCSW, Executive Director, National LGBT Cancer Network. Unfortunately, the reality of this statement is that there…
Dana-Farber Cancer Institute has just announced research updates on multiple myeloma and waldenstrom macroglobulinemia which indicate significant progress in the search for treatments for these diseases. The Findings 1) There…
According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…
According to a story from BioPortfolio, Celgene Corporation and bluebird bio, Inc., have recently announced that enrollment for a pivotal Phase 2 study testing an experimental therapy for relapsed/refractory multiple…
Rare disease research is often underrepresented in the field of science. However, recent developments have made researchers more interested in studying this group of diseases. For instance, investments in gene…
According to a story from The Oncology Times, the US Food and Drug Administration (FDA) has been moving forward with several treatments and potential treatments for a variety of different…
According to a story from Hematology Times, an experimental CAR-T cell therapy called P-BCMA-101 was recently granted regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration.…
According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…
According to a story from OncLive, the drug development company Karyopharm Therapeutics recently announced that the US Food and Drug Administration has granted Priority Review to the company's XPO1 inhibitor…
According to a story from Mother Jones, patients of black or Native American backgrounds are consistently underrepresented in clinical trials. This occurs even when the trials are for diseases that…
According to a report by the Irish Examiner, one in three people spend at least 45 hours or more caring for a someone living with cancer. Despite this being a…
A team of researchers led by Constantinos Koshiaris from the University of Oxford have recently published a study that investigated the best way to identify multiple myeloma through blood tests.…
According to a story from HSC News, Dr. Peter Kuhn from the University of South Carolina (USC) is developing a navigational tool that aims to personalize treatment based on a…
What do Dave Winfield, Steve Garvey, and Don Baylor Jr. all have in common? Besides all being big names in major league baseball, each of the famous athletes is contributing…
As vice chair of the National Comprehensive Cancer Network ‘s (NCCN) committee on multiple myeloma, Dr. Natalie Callander helps to set guidelines for effective evaluation and treatment. The NCCN commonly…
According to a story from the Washington Post, a new technique for delivering genes into immune system T cells could make immunotherapy a much more accessible option for treating rare…
Gene-editing therapies have made almost constant news headlines in relations to cancer treatment. The process of reprogramming the body’s immune cells to fight cancer seems more and more promising. The…
According to a story from Hematology Times, a medicine called melflufen, of the alkylating peptide class, appears to be effective in treatment resistant multiple myeloma. In a Phase 2 trial,…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
